Albendazole (Zentel) veterinary-grade API is the benzimidazole carbamate derivative methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate, empirical formula C₁₂H₁₅N₃O₂S, CAS 54965-21-8, molecular weight 265.33 g/mol, supplied as a white to off-white crystalline powder. The active pharmaceutical ingredient is manufactured to current USP and Ph. Eur. Albendazole monographs; typical release acceptance criteria include an HPLC assay on the dried basis of 98.0–102.0%, loss on drying ≤0.5%, sulphated ash ≤0.1%, and related-substance limits aligned with ICH Q3A thresholds. The molecule is practically insoluble in water at neutral pH and exhibits pH-dependent solubility because of the weakly basic benzimidazole nitrogen; reported pKa values are approximately 2.68 and 11.83. The Zentel designation in this context refers to the originator reference formulation; veterinary-grade Albendazole is a multi-source API used in tablets, capsules, powders, granules, premixes, oral suspensions, and—under strictly validated conditions—sterile injectable suspensions or non-aqueous injections. A veterinary API is typically supplied with a Certificate of Analysis referencing identification by infrared absorption per USP <197>, residual solvents by USP <467>, and microbial limits for non-sterile oral grades by USP <61>/<62> with total aerobic microbial count ≤1000 CFU/g and total yeast and mould count ≤100 CFU/g.

What Limits Direct Compression Performance of Albendazole in Tablet and Capsule Operations?

Unmilled Albendazole is cohesive and poorly flowing, so direct compression is normally restricted to low-dose formulations or requires force-feeder equipped tablet presses. Powder testing per USP <616> commonly shows bulk density in the range 0.25–0.45 g/mL, tapped density 0.45–0.70 g/mL, and Hausner ratio above 1.35, indicating a cohesive powder. On a rotary tablet press operated at 15–30 rpm with compression force 8–20 kN, unlubricated Albendazole at 50% drug load frequently presents capping and lamination due to low compactibility; the defect is reduced by adding microcrystalline cellulose at 30–40% w/w and crospovidone at 2–5% w/w, while magnesium stearate is limited to 0.5–1.0% w/w to avoid excessive softening. Particle size distribution by laser diffraction (ISO 13320:2020) for direct compression grades should target D90 100–150 µm with D10 above 20 µm; micronized grades with D90 below 20 µm improve dissolution but require granulation because they worsen flow and segregation.

For capsule filling, Albendazole is commonly blended with lactose monohydrate and sodium starch glycolate; encapsulation on a tamping-pin machine at 20,000–40,000 capsules/hour requires a target blend bulk density above 0.50 g/mL to maintain fill weight uniformity within USP <905> acceptance values. Pre-drying of the API at 40–50 °C for 2–4 hours is applied when ambient relative humidity exceeds 60%, because moisture adsorption promotes powder caking and die filling variability. Albendazole melts with decomposition near 208–210 °C; drying and granulation are maintained below 60 °C to avoid thermal degradation.

When high-dose tablet or granule uniformity is required, high-shear granulation of Albendazole is executed in a 300 L mixer-granulator with impeller speed 150–300 rpm and chopper speed 1500–3000 rpm. A binder solution of povidone K30 in purified water is added to a preblend of Albendazole, microcrystalline cellulose, and croscarmellose sodium; wet mass is passed through a 0.8–1.2 mm screen and dried in a fluid-bed dryer with inlet air at 50–60 °C until granule loss on drying is 1.5–2.5%. The resulting granules, typically the 0.180–0.425 mm sieve fraction, are compressed at 12–18 kN on a 16-station press. This process is preferred for high-dose tablets and for granules used in feed premixes because it reduces segregation and improves content uniformity to a relative standard deviation below 5% when sampled at 10 locations in a V-blender.

Suspension Rheology and Crystal Growth Control in High-Dose Oral Drenches

For oral suspensions, Albendazole is micronized in a recirculating bead mill with 0.4–0.6 mm yttria-stabilized zirconium oxide beads to a target D90 of ≤15 µm by laser diffraction (ISO 13320:2020). The micronization step increases specific surface area and requires a wetting and dispersing system; polysorbate 80 at 0.05–0.2% w/v and sorbitan monooleate are used ahead of the bead mill to reduce foam and improve particle wetting. Because Albendazole pKa values are approximately 2.68 and 11.83, maximal solubility occurs below pH 3, but accelerated carbamate hydrolysis under strongly acidic conditions makes pH 4.0–5.5 the working range for oral drenches. Suspensions buffered with citrate or phosphate are thickened with xanthan gum at 0.15–0.35% w/v and microcrystalline cellulose/carboxymethylcellulose at 0.5–1.0% w/v to achieve an apparent viscosity of 800–1500 mPa·s at 20 °C using a Brookfield RVDV viscometer spindle 2 at 20 rpm. Sedimentation volume is monitored after 24 hours; redispersibility is checked by manual inversion of the commercial container for 30 seconds. Particle size growth during storage is controlled by limiting the span (D90-D10)/D50 to below 2.5 and by storing at 15–25 °C; freeze–thaw cycles are avoided because they induce crystal bridging and hard caking.

Microbiological robustness of oral suspensions follows USP <61>/<62> and Ph. Eur. 2.6.12/2.6.13; preservative efficacy testing per USP <51> is required for multidose containers. Sodium benzoate at 0.1–0.2% w/v or potassium sorbate at 0.1–0.2% w/v is selected after confirming pH compatibility. Oxidation of the propylthio group is a degradation pathway; therefore sodium metabisulphite at 0.1% w/v may be included, but it is incompatible with containers that leach transition metals.

Because the aqueous solubility of Albendazole at pH 6.8 is below 10 µg/mL, a sterile injectable presentation cannot be produced by simple reconstitution of oral-grade API. Published data for specific injectable configurations is limited, and regulatory acceptance requires target animal safety and bioequivalence data under VICH GL43 and VICH GL52. Injectable formulations are designed either as non-aqueous cosolvent vehicles based on glycerol formal, propylene glycol, or polyethylene glycol 400, or as sterile micronized suspensions with D99 ≤20 µm to minimize capillary obstruction. Terminal moist-heat sterilization at 121 °C is generally unsuitable because the carbamate linkage undergoes hydrolysis; candidate sterilization approaches include sterile filtration of the vehicle and gamma irradiation of the micronized API at 15–25 kGy. Syringeability is evaluated through 21-gauge needles per ISO 7886-1, and the injection volume must be restricted to species-appropriate depots. For food-producing species, withdrawal periods must follow the national or regional maximum residue limit framework; the active marker residue is albendazole sulfoxide, not the parent API.

For feed premix manufacture, geometric dilution of micronized Albendazole with a free-flowing carrier such as ground corn cob or lactose monohydrate is used. Homogeneity is assessed by near-infrared spectroscopy calibrated against HPLC; the final blend coefficient of variation should remain below 5% RSD after 10 minutes of mixing in a ribbon blender at 50–70% fill volume. Granulation for feed use is carried out by extrusion-spheronization with microcrystalline cellulose and starch at water content 30–35%; extruder screen size 0.8–1.4 mm and spheronizer plate speed 800–1200 rpm produce granules that are dried to loss on drying ≤3% at 50 °C. Segregation tests in a 1 m³ tote show that Albendazole granules with D50 0.6–0.8 mm remain stable under vibration, while powder blends with D90 below 20 µm segregate rapidly unless agglomerated or formulated with high-viscosity binders.

In dissolution method development, Albendazole solid forms are complicated by low aqueous solubility and pH-dependent ionization of the benzimidazole ring. Initial testing generally uses USP apparatus 2 at 75 rpm with 900 mL of 0.1 M hydrochloric acid containing 0.5–1.0% sodium lauryl sulfate, followed by a pH shift to phosphate buffer at pH 6.8 to mimic abomasal and intestinal passage. Published data for compendial veterinary dissolution conditions is limited; therefore each formulation is qualified against target-species bioavailability data rather than relying on a fixed Q value. Batch-to-batch variability in micronized particle size, especially D90 above 20 µm, can reduce dissolution rate and alter albendazole sulfoxide exposure in ruminants, so particle size is a release-controlled parameter for suspension and feed premix grades.

During long-term storage, Albendazole API should be kept in double polyethylene bags inside a fiber drum at 15–30 °C with relative humidity below 60%. The material should not be combined with strong oxidizing agents because of sulfoxide formation, and contact with acids below pH 3 should be limited to short dissolution testing rather than storage. For aqueous suspensions, stainless steel 316L tanks are preferred over carbon steel because leached iron accelerates oxidative degradation; glass-lined vessels are also used. For feed premixes, compatibility with ionophore coccidiostats must be checked before medicated feed assembly, because mixing sequence and particle size differences can create segregation and cross-contamination during pelleting at conditioning temperatures above 80 °C.

Albendazole Versus Fenbendazole, Oxfendazole, and Mebendazole: Key Formulation Variables

Albendazole, fenbendazole, oxfendazole, and mebendazole share the benzimidazole core but differ in ring substitution, metabolic activation, solubility, and approved species. Albendazole is rapidly oxidized in the liver to albendazole sulfoxide, the primary anthelmintic moiety, and then to albendazole sulfone. Fenbendazole is converted to oxfendazole; oxfendazole is itself active and persists longer in plasma. Mebendazole has a benzoyl substituent and exhibits poor systemic absorption, which favors gastrointestinal lumen exposure but limits tissue-stage efficacy. These pharmacokinetic differences influence formulation: Albendazole requires relatively fine particle size and sometimes lipid or acidified vehicles to improve oral absorption, whereas fenbendazole paste and granules are formulated for equine and companion species where its slower dissolution is less limiting. Table 1 summarizes key comparative attributes for dosage form selection.

When a Supplier Specification Must Align With ICH and VICH Quality Thresholds

Release testing for veterinary-grade Albendazole is organized around compendial monographs plus residual-solvent and elemental-impurity requirements. Table 2 lists a typical specification matrix for oral solid and suspension grades; sterile injectable grades require additional bacterial endotoxin testing per Ph. Eur. 2.6.14 and sterility per Ph. Eur. 2.6.1, and the oral-grade specification is not sufficient for injectable use.